MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Начало・Списък с акции・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Затворен

1.53 4.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.4

Максимум

1.53

Ключови измерители
By Trading Economics
Приходи	-215K -12M
EPS	-0.21
Служители	37
EBITDA	-170K -12M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+302.68% upside

Дивиденти
By Dow Jones
Следващи печалби	3.04.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	56M
Предишно отваряне	-2.55
Предишно затваряне	1.53

Actinium Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 23:55 ч. UTC

Горещи акции

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2.04.2025 г., 22:50 ч. UTC

Значими двигатели на пазара

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2.04.2025 г., 21:08 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2.04.2025 г., 21:00 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2.04.2025 г., 23:56 ч. UTC

Пазарно говорене

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Топ новини

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2.04.2025 г., 23:10 ч. UTC

Пазарно говорене

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:57 ч. UTC

Пазарно говорене

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2.04.2025 г., 22:43 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2.04.2025 г., 22:12 ч. UTC

Пазарно говорене

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2.04.2025 г., 21:48 ч. UTC

Топ новини

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2.04.2025 г., 21:41 ч. UTC

Пазарно говорене

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2.04.2025 г., 21:04 ч. UTC

Топ новини

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2.04.2025 г., 21:03 ч. UTC

Пазарно говорене

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2.04.2025 г., 20:53 ч. UTC

Печалби

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2.04.2025 г., 20:52 ч. UTC

Печалби

Kaiser Aluminum Changes Inventory Acctg Methodology

Сравнение с други в отрасъла

Ценова промяна

Actinium Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

302.68% нагоре

12-месечна прогноза

Среден 6 USD 302.68%

Висок 9 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Actinium Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Actinium Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.